Investigating a new drug to prevent oral cavity cancers
Official title: CD 1530, an RAR Gamma Agonist for Oral Cavity Squamous Cell Carcinoma Prevention
Funded at Weill Medical Coll of Cornell Univ · NIH-10927202 · Data updated 2026-11-12
This study is looking at a new drug called CD1530 that might help prevent a type of mouth cancer by changing how cells in the mouth behave, and it could lead to trials for patients to see if it works safely for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 11, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $434,366 |
| NIH project number | 5R01CA270248-02 |
| Project ID | NIH-10927202 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at high risk for oral cavity squamous cell carcinoma, particularly those with a history of tobacco use or other risk factors.
✕Less likely to help
Patients who have already been diagnosed with advanced oral cavity cancers may not benefit from this preventive approach.
What this research studies
This research focuses on the use of CD1530, a selective agonist for the retinoic acid receptor gamma (RARγ), to prevent oral cavity squamous cell carcinoma. The study aims to understand how this drug can alter the transcriptional profile of cells in the oral cavity to reduce the risk of cancer development. By utilizing a murine model, researchers have shown promising results in reducing carcinoma formation, indicating potential for human application. Patients may be involved in trials to assess the effectiveness and safety of this preventive treatment.
Why it matters
Potential benefit: If successful, this research could significantly lower the incidence of oral cavity cancers, improving survival rates and quality of life for patients at risk.
How similar studies have gone: Previous research has shown success with similar approaches using retinoic acid receptor agonists in cancer prevention, suggesting a promising avenue for this study.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Gudas, Lorraine J — Weill Medical Coll of Cornell Univ
- Study coordinator: Gudas, Lorraine J
Related research
Other NIH-funded projects on the same topics.
-
Novel idea: Epstein-Barr virus and eye cancer in people living with HIV in Zimbabwe
A study explores whether Epstein-Barr virus could cause a type of eye cancer in people living with HIV in Zimbabwe.
-
Oral cancer recurrence predictor using tumor microbes and gene activity
This NIH grant explores how bacteria and immune signals inside oral cancer tumors relate to whether the cancer comes back, with the aim of making a practical risk predictor for patients.
-
Data-driven classification of aggressive tissue traits to predict cancer outcomes in HPV-negative head and neck cancer
A clinician-science grant uses data science and AI to identify tissue patterns in HPV-negative head and neck cancer that may predict how long patients stay cancer-free.
-
Targeting PIPKIγi5 to boost immune responses against head and neck cancer
A study to see if blocking a specific enzyme, PIPKIγi5, can make head and neck cancer more visible to the immune system and more responsive to existing immunotherapies.
-
Targeted approaches for lung squamous cell carcinoma with key gene changes
A study at a major university is exploring new targets in lung squamous cell carcinoma to help people with this cancer find better treatments.
-
Baculovirus-based therapy to treat head and neck cancer with a gentle, minimally invasive approach
A new, minimally invasive approach using baculovirus-delivered CRISPR gene editing aims to treat head and neck squamous cell carcinoma while aiming to preserve essential tissues.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.